Four corporate executives in Navidea Biopharmaceuticals (NAVB) made insider buys into the company on Friday. These buys mark the first insider transactions for Navidea in 2013. Chief Business Officer and Executive Vice President Thomas Tulip bought 17,500 shares for $2.82 costing him $49,350. Tulip now holds on to 49,350 shares. Senior Vice President, William Regan, added 5,000 shares at $2.71 to his stake. This transaction cost Regan $13,550; he now owns 5,000 shares of the company. Director Brendan Ford also added 5,000 shares, costing him $13,550. Ford now holds 119,250 shares of Navidea. Lastly, CEO and President Mark Pykett added 1,850 shares at $2.70 costing him a total of $4,995.
Thomas Tulip has been with Navidea since June 2010. He is also on the Board of Directors at the Council on Radionuclides and Radiopharmaceuticals (ORAR). Tulip helped develop and commercialize the first nuclear cardiology franchise.
Brendan Ford has been a partner with Navidea since 2010. He is a corporate partner with Talisman Capital Partners, a private investment partnership that focuses on middle market companies.
William Regan is the Senior Vice President of Global Regulatory Strategy for Navidea. Regan is just starting with the company. This insider buy marks the first one for Regan.
Mark Pykett has been the CEO and President of Navidea since April 2011. Pykett has worked in the pharmaceutical industry for over 15 years. He holds a degree in veterinary medicine and a Ph.D. in molecular biology from the University of Pennsylvania.
Navidea Biopharmaceuticals is a biopharmaceutical company that focuses on developing radiopharmaceutical imaging agents that help identify the presence and status of disease and enable better diagnostic accuracy. Navidea is based out of Dublin, Ohio, and has a market cap of $286.73 million.
Revenues for 2012 were $79,000 compared to $598,000 for 2011. Operating expenses for 2012 were $28.1 million compared to $24.7 million for 2011. Navidea reports that revenues were down in 2012 due to the reimbursement of Lymphoseek commercialization activities. In February 2013 the company completed an underwritten public offering of 1.5 million shares of common stock.
“During 2012, we continued to make important progress positioning Navidea as a leader in the area of precision diagnostics,” said Dr. Mark Pykett, Navidea’s president and CEO. “We are looking forward to an even more exciting 2013.”
There are currently no Gurus followed by GuruFocus that hold shares in Navidea Biopharmaceuticals.
With its shares up 3.37%, Navidea trades at $2.76.
For more information on insider trades within NAVB look at the Navidea Biopharmaceuticals Insider Trade History page.
Thomas Tulip has been with Navidea since June 2010. He is also on the Board of Directors at the Council on Radionuclides and Radiopharmaceuticals (ORAR). Tulip helped develop and commercialize the first nuclear cardiology franchise.
Brendan Ford has been a partner with Navidea since 2010. He is a corporate partner with Talisman Capital Partners, a private investment partnership that focuses on middle market companies.
William Regan is the Senior Vice President of Global Regulatory Strategy for Navidea. Regan is just starting with the company. This insider buy marks the first one for Regan.
Mark Pykett has been the CEO and President of Navidea since April 2011. Pykett has worked in the pharmaceutical industry for over 15 years. He holds a degree in veterinary medicine and a Ph.D. in molecular biology from the University of Pennsylvania.
Navidea Biopharmaceuticals is a biopharmaceutical company that focuses on developing radiopharmaceutical imaging agents that help identify the presence and status of disease and enable better diagnostic accuracy. Navidea is based out of Dublin, Ohio, and has a market cap of $286.73 million.
Revenues for 2012 were $79,000 compared to $598,000 for 2011. Operating expenses for 2012 were $28.1 million compared to $24.7 million for 2011. Navidea reports that revenues were down in 2012 due to the reimbursement of Lymphoseek commercialization activities. In February 2013 the company completed an underwritten public offering of 1.5 million shares of common stock.
“During 2012, we continued to make important progress positioning Navidea as a leader in the area of precision diagnostics,” said Dr. Mark Pykett, Navidea’s president and CEO. “We are looking forward to an even more exciting 2013.”
There are currently no Gurus followed by GuruFocus that hold shares in Navidea Biopharmaceuticals.
With its shares up 3.37%, Navidea trades at $2.76.
For more information on insider trades within NAVB look at the Navidea Biopharmaceuticals Insider Trade History page.
